中华眼底病杂志

中华眼底病杂志

阿柏西普玻璃体腔注射和光动力疗法治疗中国新生血管性老年性黄斑变性患者的疗效对比:SIGHT研究

查看全文

目的对比观察玻璃体注射阿柏西普(IAI)和光动力疗法(PDT)治疗中国继发于新生血管性老年性黄斑变性(nAMD)的经典为主型脉络膜新生血管(CNV)患者的安全性和有效性。方法随机、双盲、多中心为期52周(2011年12月至2014年8月)的Ⅲ期临床研究。研究注册码NCT01482910。入组患者按照3:1比例随机分为IAI组、PDT→IAI组。IAI组患者在基线和第4、8、16、24、32、40、48周时接受2 mg IAI治疗,第28、36周时分别接受假注射治疗。PDT→IAI组患者在基线时均强制接受1次PDT治疗,第12、24周时若满足PDT再治疗条件,则再次予以PDT治疗;基线和第4、8、16、24周时接受假注射治疗,第28、32、36、40、48周时接受2 mg IAI治疗。报告的主要有效性结果为第28周时平均BCVA相较基线的变化和第52周时的结果。安全性评价包括发生治疗相关不良事件(TEAEs)患者百分比。结果入组304例患者中,IAI组、PDT→IAI组分别为228、76例。第28周时,IAI组、PDT→IAI组患者平均BCVA较基线变化值分别为+14.0、+3.9个字母;第52周时,两组患者BCVA较基线变化值分别为+15.2、+8.9个字母,差异为+6.2个字母(95% CI 2.6~9.9,P=0.000 9)。第52周时,两组患者平均中心凹视网膜厚度分别下降−189.6、−170.0 μm。IAI组中BCVA提高最为显著者为年龄<65岁、活动性CNV面积<总病灶面积50%者。IAI组、PDT→IAI组患者眼部最常见TEAEs为黄斑纤维化[11.8%(27/228)、6.6%(5/76)]、BCVA下降[6.6%(15/228)、21.1%(16/76)]。抗血小板研究合作组定义的动脉血栓栓塞事件3例,但均被认为与药物无关。结论中国nAMD患者阿柏西普治疗效果优于PDT。阿柏西普疗效在全部患者中均可持续至第52周。不良事件的发生率与已知的阿柏西普安全性数据一致。

ObjectiveTo assess the efficacy and safety of intravitreal aflibercept injection (IAI) compared with photodynamic therapy (PDT) in the treatment of Chinese patients with predominantly classic subfoveal choroidal neovascularization (CNV) lesions secondary to neovascular age-related macular degeneration (nAMD).MethodsA randomized, double-blind, multi-center phase-3 clinical trial lasting for 52 weeks (from December 2011 to August 2014). Subjects were randomized in a 3:1 ratio to either IAI group or PDT-to-IAI group. Subjects in the IAI group received 2 mg IAI at baseline and at week 4, 8, 16, 24, 32, 40, 48, with sham injection at week 28, 36. Subjects in the PDT-to-IAI group were forced to receive PDT once at baseline and more time at week 12, 24 if PDT retreatment conditions were met. Sham injections were given in PDT-to-IAI group at baseline and at week 4, 8, 16 and 24, followed by 2 mg IAI at week 28, 32, 36, 40, 48. The primary outcome of efficacy were the change in mean Best Corrected Visual Acuity (BCVA) from baseline to week 28, and that of week 52. Safety evaluation included the percentage of subjects who suffered treatment emergent adverse events (TEAEs).ResultsAmong the 304 subjects enrolled, there were 228 and 76 cases in IAI group and PDT-to-IAI group respectively. At week 28, the changes of mean BCVA in IAI group, PDT-to-IAI group compared to baseline were +14.0, +3.9 letters, respectively. At week 52, the changes of mean BCVA in two groups were +15.2, +8.9 letters respectively with the difference of +6.2 letters (95%CI 2.6−9.9, P=0.000 9). At week 52, the mean foveal retinal thickness in the two groups decreased by −189.6, −170.0 μm, respectively. Subjects with the most BCVA increase in IAI group were those aged <65, and those with active CNV lesion area <50% of total lesion area. The most common TEAEs in IAI group and PDT-to-IAI group are macular fibrosis [11.8% (27/228), 6.6% (5/76)] and BCVA decline [6.6% (15/228), 21.1% (16/76)]. There were 3 cases of arterial thromboembolic events defined in the antiplatelet experimental collaboration group, but all were considered unrelated to interventions.ConclusionsThe efficacy of aflibercept is superior to that of PDT in nAMD patients in China. The therapeutic effect of aflibercept persisted to week 52 in all subjects. The rate of adverse events was consistent with the safety data of aflibercept known before.

关键词: 湿性黄斑变性/药物疗法; 脉络膜新生血管化/药物疗法; 血管生成抑制剂/治疗应用; 抗体, 单克隆/治疗应用; 光化学疗法

Key words: Wet macular degeneration/drug therapy; Choroidal neovascularization/drug therapy; Angiogenesis inhibitors/therapeutic use; Antibodies, monoclonal/therapeutic use; Photochemotherapy

引用本文: 黎晓新, 陈有信, 张军军, 许迅, 张风, ChuiMing Gemmy Cheung, RuiYu, HusainKazmi, OlafSowade, OliverZeitz on behalf of the SIGHT study group. 阿柏西普玻璃体腔注射和光动力疗法治疗中国新生血管性老年性黄斑变性患者的疗效对比:SIGHT研究. 中华眼底病杂志, 2019, 35(2): 156-165. doi: 10.3760/cma.j.issn.1005-1015.2019.02.010 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Wong WL, Su X, Li X, et al. Global prevalence of agerelated macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis[J]. Lancet Glob Health, 2014, 2(2): 106-116. DOI: 10.1016/S2214-109X(13)70145-1.
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration[J]. N Engl J Med, 2006, 355(14): 1432-1444. DOI: 10.1056/NEJMoa062655.
3. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study[J]. Ophthalmology, 2009, 116(1): 57-65. DOI: 10.1016/j.ophtha.2008.10.018.
4. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report[J]. Arch Ophthalmol, 1999, 117(10): 1329-1345. DOI: 10.1001/archopht.117.10.1329.
5. 陈有信, 葛坚, 严密, 等. 中国维替泊芬光动力疗法治疗年龄相关性黄斑变性中心凹下脉络膜新生血管的多中心临床研究[J]. 中华眼科杂志, 2007, 43(3): 198-205. DOI: 10.3760/j.issn.0412-4081.2007.03.003.Chen YX, Ge J, Yan M, et al. Clinical trial of verteporfin photodynamic therapy in Chinese age-related macular degeneration with subfoveal predominant choroidal neovascularization patients[J]. Chin J Ophthalmol, 2007, 43(3): 198-205. DOI: 10.3760/j.issn.0412-4081.2007.03.003.
6. Yoon JU, Byun YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization[J]. Retina, 2010, 30(3): 418-424. DOI: 10.1097/IAE.0b013e3181bd2fe4.
7. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration[J]. Ophthalmology, 2012, 119(12): 2537-2548. DOI: 10.1016/j.ophtha.2012.09.006.
8. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEWstudies[J]. Ophthalmology, 2014, 121(1): 193-201. DOI: 10.1016/j.ophtha.2013.08.011.
9. Wong TY, Ogura Y. 2-year (96-week) efficacy and safety of intravitreal aflibercept injection for neovascular age-related macular degeneration in Asian patients: subgroup analysis of VIEW studies[C]. World Ophthalmology Congress, Tokyo, Japan, 2014.
10. Sivaprasad S, Saleh GM, Jackson H. Does lesion size determine the success rate of photodynamic therapy for agerelated macular degeneration?[J]. Eye (Lond.), 2006, 20(1): 43-45. DOI: 10.1038/sj.eye.6701787.
11. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update[J]. Retina, 2005, 25(2): 119-134. DOI: 10.1097/00006982-200502000-00002.
12. Suner IJ, Kokame GT, Yu E, et al. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials[J]. Invest Ophthalmol Vis Sci, 2009, 50(8): 3629-3635. DOI: 10.1167/iovs.08-3225.
13. Brown DM, Shapiro H, Schneider S. Subgroup analysis of first-year results of ANCHOR: a phase Ⅲ, double-masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age-related macular degeneration[J]. Invest Ophthalmol Vis Sci, 2006, 47: 2963.
14. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results[J]. Am J Ophthalmol, 2007, 144(6): 850-857. DOI: 10.1016/j.ajo.2007.08.012.
15. ICH Harmonised Tripartite Guideline. Ethnic factors in the acceptability of foreign clinical data EH(R1)[EB/OL](2016-04-18). http://www.ich.org/products/guidelines/efficacy/article/efficacyguidelines.html.